Thyroid-stimulating hormone receptor polypeptide agonist glycoforms to treat metabolic syndrome
展开▼
机译:促甲状腺激素受体多肽激动剂糖型治疗代谢综合征
展开▼
页面导航
摘要
著录项
相似文献
摘要
TSHR agonists that are substantially desialylated are described for treating metabolic syndrome and obesity and for inducing lipolysis. The TSHR polypeptide agonists are useful for treatment of hallmarks of metabolic syndrome: obesity, insulin resistance, hyperlipidemia, and liver steatosis, without producing a hyperthyroid state in treated individuals.
展开▼